Teligent is a specialty generic pharmaceutical company (NASDAQ: TLGT). Our mission is to be a leading player in the specialty generic prescription drug market.

We have 16 Abbreviated New Drug Applications (ANDAs) on file at the FDA, representing a total addressable market of approximately $1.4 billion (IQVIA, April 2019).

We sell a portfolio of prescription topical medicines and a growing number of hospital-based sterile injectable products, including cephalosporins.

"We are forging the path to profitable growth and will continue to make the tough decisions needed to grow this business responsibly."

Damian Finio

Recent News

Teligent, Inc. Announces Transition in Leadership

BUENA, N.J. , Feb. 05, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jerse...

Learn More

Teligent, Inc. Announces FDA Request for Further Data on Complex Drug

BUENA, N.J. , Dec. 23, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pha...

Learn More

Teligent, Inc. to Present at Jefferies Global Healthcare Conference in London on Wednesday November 20, 2019

BUENA, N.J. , Nov. 13, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey based specialty generic phar...

Learn More


Investor Overview

Stock Information

Copyright West LLC. Minimum 15 minutes delayed.